Praful Mehta
Psychiatry · Charlotte, NCNPI 1376660530
Payments from drug & device makers
Across 213 payments — averaging $30.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$1K
- Johnson & Johnson$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$680
- AbbVie$561
- Neurocrine Biosciences, Inc.$440
- plus $875 from 10 others
What the payments were for
- Food & beverage$6,407100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 47 | $1,465 |
| Alkermes, Inc. | 41 | $1,236 |
| Johnson & Johnson | 36 | $1,154 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $680 |
| AbbVie(2 entities) | 24 | $561 |
| Neurocrine Biosciences, Inc. | 17 | $440 |
| E.r. Squibb & Sons, L.L.C. | 6 | $220 |
| Sunovion Pharmaceuticals Inc. | 7 | $179 |
| Supernus Pharmaceuticals, Inc. | 7 | $134 |
| Teva Pharmaceuticals USA, Inc. | 5 | $106 |
| Lundbeck LLC | 5 | $95 |
| Vanda Pharmaceuticals Inc. | 4 | $54 |
| Indivior Inc. | 2 | $31 |
| Luye Pharma (USA) Ltd. | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$979
- CAPLYTA$598
- LYBALVI$497
- INVEGA SUSTENNA$275
- ARISTADA INITIO$245
- VRAYLAR$242
- COBENFY$125
- ABILIFY MAINTENA$123
- ABILIFY ASIMTUFII$123
- REXULTI$123
- LATUDA$122
How this compares
$6,412 in reported general payments places this provider in the 85th percentile of 1,108 psychiatry providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 22 | $76,185 |
| Haloperidol | 19 | $1,307 |
| Ziprasidone Hcl | 12 | $626 |
| Hydroxyzine Hcl | 12 | $381 |
| Divalproex Sodium ErDivalproex Sodium | 11 | $310 |
| Benztropine Mesylate | 19 | $310 |
| Buspirone Hcl | 15 | $307 |
| Hydroxyzine Pamoate | 15 | $250 |
| Lithium Carbonate ErLithium Carbonate | 11 | $230 |
| Gabapentin | 11 | $171 |
| Prazosin Hcl | 12 | $130 |
| Trazodone Hcl | 24 | $104 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $1,154 | $76,18522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,108 psychiatry providers in North Carolina.
Other psychiatry in Charlotte
- Oleg TcheremissineCharlotte$2M
- Vivian CampbellCharlotte$103K
- Keith LoganCharlotte$57K
- Anne RichardsonCharlotte$48K
- Devendra ShahCharlotte$24K
- Craig ChepkeHuntersville$4.1M
- James BarkerHickory$4.1M
- Mark ReynoldsDurham$3.2M
- Richard WeislerRaleigh$1.2M
- Dan BlazerDurham$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.